Renal Cell Carcinoma Clinical Trials 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.Sequential Treatment of Cabozantinib or Cabozantinib With Nivolumab for Advanced Renal Cell Carcinoma (RCC)
Conditions: RCC; Renal Cell Carcinoma Interventions: Drug: Cabozantinib 80 MG; Drug: Cabozantinib 40Mg Tab; Drug: Nivolumab Sponsors: University of Texas Southwestern Medical Center; Exelixis Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 5, 2023 Category: Research Source Type: clinical trials
